-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

Benzinga·08/07/2026 18:34:49
Listen to the news
RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.